- Home
- ABBV
ABBV
AbbVie Inc.
as 06-06-2025 4:00pm EST
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | NORTH CHICAGO |
| Market Cap: | 325.1B | IPO Year: | N/A |
| Target Price: | $211.55 | AVG Volume (30 days): | 6.6M |
| Analyst Decision: | Buy | Number of Analysts: | 23 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 2.34 | EPS Growth: | -30.38 |
| 52 Week Low/High: | $163.52 - $218.66 | Next Earning Date: | 07-24-2025 |
| Revenue: | $57,367,000,000 | Revenue Growth: | 5.45% |
| Revenue Growth (this year): | 8.5% | Revenue Growth (next year): | 8.20% |
Stock Insider Trading Activity of AbbVie Inc. (ABBV)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Stewart Jeffrey Ryan | ABBV | EVP, CHIEF COMMERCIAL OFFICER | Mar 31 '25 | Sell | $210.02 | 58,832 | $12,359,504.28 | 86,366 | |
| Reents Scott T | ABBV | EVP, CHIEF FINANCIAL OFFICER | Mar 14 '25 | Sell | $212.34 | 17,644 | $3,746,526.96 | 11,577 |
Latest AbbVie Inc. News
ABBV Breaking Stock News: Dive into ABBV Ticker-Specific Updates for Smart Investing
Motley Fool
7 hours ago
3 Stocks With Mouthwatering Dividends You Can Buy Right Now
Yahoo Finance Video
2 days ago
Challenges pharma companies face in push into US manufacturing
Zacks
2 days ago
Can New Cancer Drug Emrelis Drive AbbVie's Oncology Franchise?
Zacks
3 days ago
AbbVie (ABBV) Increases Despite Market Slip: Here's What You Need to Know
Motley Fool
3 days ago
Billionaire Ken Griffin Just Bought More Shares of These Unstoppable Dividend Stocks
StockStory
4 days ago
AbbVie (ABBV): Buy, Sell, or Hold Post Q1 Earnings?
Zacks
4 days ago
Profit From the Silver Tsunami: Must-Watch Senior Care & Aging Stocks
Motley Fool
4 days ago
3 Cheap Dividend Growth Stocks to Buy Right Now
Compare ABBV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ABBV AbbVie Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.